

I. AMENDMENTS

In the claims:

1. (currently amended): An immunogenic composition comprising:
~~a plasmid comprising a sequence encoding an immunogen-a DNA immunogen; and~~
a B lymphocyte-~~chemokine chemoattractant~~ (BLC) or a polynucleotide encoding a B lymphocyte ~~chemokine chemoattractant~~ (BLC).
2. (currently amended): The immunogenic composition of claim 1 wherein the ~~immunogen is DNA immunogen comprises a polynucleotide encoding~~ a viral immunogen.
3. (currently amended): The immunogenic composition of claim 2 wherein the ~~viral immunogen is polynucleotide encodes~~ a hepatitis C virus non-structural polypeptide.
4. (original): The immunogenic composition of claim 3 wherein the hepatitis C virus non-structural polypeptide is selected from the group consisting of NS3, NS4, NS5a, and NS5b.
5. (currently amended): The immunogenic composition of claim 2 wherein the ~~viral immunogen is polynucleotide encodes~~ an HIV polypeptide.
6. (original): The immunogenic composition of claim 5 wherein the HIV polypeptide is a gag polypeptide.
7. (currently amended): The immunogenic composition of claim 1 wherein the ~~DNA immunogen comprises a polynucleotide encoding an immunogen expressed by a tumor immunogen~~.
- 8 and 9. (canceled)
10. (original): The immunogenic composition of claim 1 further comprising a pharmaceutically acceptable carrier.
11. (currently amended): A method of enhancing an immune response to ~~a DNA-a viral immunogen~~ in a mammal comprising the step of:
intramuscularly or intradermally administering to the mammal (i) a chemokine or a first polynucleotide encoding a chemokine and (ii) a ~~plasmid comprising a sequence encoding a viral DNA-immunogen~~, whereby an immune response to the ~~DNA viral~~ immunogen is enhanced.

12. (original): The method of claim 11 wherein a chemokine is administered.

13. (currently amended): The method of claim 12 wherein the chemokine and the DNA immunogen plasmid are co-administered.

14. (currently amended): The method of claim 12 wherein the chemokine is administered prior to the administration of the DNA immunogen plasmid.

15. (currently amended): The method of claim 12 wherein the DNA immunogen plasmid is administered prior to administration of the chemokine.

16. (original): The method of claim 11 wherein the first polynucleotide encoding the chemokine is administered.

17. (currently amended): The method of claim 16 wherein the first polynucleotide and the DNA immunogen plasmid are co-administered.

18. (currently amended): The method of claim 16 wherein the first polynucleotide is administered prior to the administration of the plasmid.

19. (currently amended): The method of claim 16 wherein the DNA immunogen plasmid is administered prior to the administration of the first polynucleotide.

20. (currently amended): The method of claim 16 wherein a second polynucleotide is administered, the second polynucleotide comprising which comprises (a) the first polynucleotide and (b) the DNA immunogen a sequence encoding a viral immunogen is administered.

21. (original) The method of claim 11 wherein the chemokine is macrophage inflammatory protein 1 α (MIP-1 α).

22. (currently amended): The method of claim 11 wherein a chemokine is B lymphocyte chemokine chemoattractant (BLC).

23. (currently amended): The method of claim 11 wherein the DNA immunogen comprises a polynucleotide encodes viral immunogen is a hepatitis C virus non-structural polypeptide.

24. (original): The method of claim 23 wherein the hepatitis C virus non-structural polypeptide is selected from the group consisting of NS3, NS4, NS5a, and NS5b.

25. (currently amended): The method of claim 11 wherein the ~~polynucleotide encodes~~ viral immunogen is an HIV polypeptide.

26. (original): The method of claim 25 wherein the HIV polypeptide is a gag polypeptide.

B
27. (original): The method of claim 11 wherein the mammal is human.

28. (original): The method of claim 11 wherein the immune response is an antibody response.

29. (original): The method of claim 11 wherein the immune response is a cytotoxic T lymphocyte response.
